Sintilimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade

Description of Sintilimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade

Introduction

Sintilimab Biosimilar, also known as Anti-PDCD1, PD1, CD279 mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Sintilimab. It is designed to target the programmed cell death protein 1 (PD-1), also known as CD279, which is a key immune checkpoint receptor involved in regulating the immune response. In this article, we will discuss the structure, activity, and application of Sintilimab Biosimilar in the field of immunotherapy.

Structure of Sintilimab Biosimilar

Sintilimab Biosimilar is a recombinant humanized IgG4 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, linked together by disulfide bonds. The variable regions of the antibody are derived from the mouse anti-PD-1 antibody, while the constant regions are of human origin. This structure allows the antibody to effectively bind to and block the PD-1 receptor, thus inhibiting its function.

Mechanism of Action

The main function of Sintilimab Biosimilar is to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This interaction is crucial for the suppression of T cell activity, as it inhibits the production of cytokines and proliferation of T cells. By blocking this interaction, Sintilimab Biosimilar restores the activity of T cells, leading to enhanced anti-tumor immune response.

Therapeutic Applications

Sintilimab Biosimilar has shown promising results in the treatment of various types of cancer, including non-small cell lung cancer, melanoma, and Hodgkin’s lymphoma. It has been approved for use in combination with chemotherapy for the treatment of advanced or metastatic non-small cell lung cancer in China. In addition, Sintilimab Biosimilar is currently being evaluated in clinical trials for the treatment of other types of cancer, such as gastric cancer and hepatocellular carcinoma.

Research Grade

Sintilimab Biosimilar is also available as a research grade antibody, which is used for in vitro and in vivo studies to understand its mechanism of action and potential therapeutic applications. The research grade antibody is produced using the same technology as the therapeutic antibody, ensuring high quality and consistency.

Advantages of Sintilimab Biosimilar

Compared to the original therapeutic antibody, Sintilimab Biosimilar offers several advantages. Firstly, it is more cost-effective, making it more accessible for patients. Secondly, as a biosimilar, it has been shown to have similar efficacy and safety profiles as the original antibody, making it a reliable alternative for treatment. Additionally, Sintilimab Biosimilar has a shorter production time, allowing for faster availability and potential for wider use.

Conclusion

Sintilimab Biosimilar, also known as Anti-PDCD1, PD1, CD279 mAb, is a promising monoclonal antibody that has shown potential in the treatment of various types of cancer. Its ability to block the PD-1 receptor and restore T cell activity makes it a valuable addition to the field of immunotherapy. With its cost-effectiveness and comparable efficacy to the original therapeutic antibody, Sintilimab Biosimilar has the potential to improve the accessibility of cancer treatment for patients worldwide.

Sintilimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Sintilimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb (cat. No.PX-TA1536) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450